UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
Rhea-AI Summary
UroGen Pharma (Nasdaq: URGN) will present at the Guggenheim Securities Emerging Outlook: Biotech Summit on February 12, 2026 at 2:30 PM ET in New York.
Format includes a fireside chat and 1x1 investor meetings. A live webcast will be available on UroGen’s Events & Presentations page, with a replay accessible for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – URGN
In the Feb 4 session, URGN gained 3.55%, reflecting a moderate positive market reaction. Argus tracked a peak move of +15.4% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Reimbursement / access | Positive | -2.5% | Permanent HCPCS J9282 code for ZUSDURI to streamline billing and access. |
| Dec 05 | Equity compensation | Neutral | -4.8% | RSU inducement grants for new employees under Nasdaq Listing Rule 5635(c)(4). |
| Nov 25 | Conference appearance | Neutral | +2.8% | Announcement of a fireside chat at the Piper Sandler healthcare conference. |
| Nov 06 | Earnings and update | Positive | +21.9% | Q3 2025 results with growing Jelmyto and initial ZUSDURI revenues and cash update. |
| Nov 06 | Clinical data update | Positive | +21.9% | Phase 3 UTOPIA trial CR rates for UGN-103 and FDA agreement on NDA strategy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive catalysts (earnings, clinical data) have coincided with strong gains, while administrative or access-related news and equity grants have sometimes seen negative or muted reactions.
Over the last few months, UroGen has reported several important milestones. On Nov 6, 2025, Q3 2025 earnings and related disclosures highlighted revenue growth and ZUSDURI launch momentum, with the stock rising about 21.9%. The same day, Phase 3 UTOPIA results for UGN-103 and FDA alignment on an NDA strategy also saw a similar positive move. In contrast, administrative items like inducement grants on Dec 5, 2025 and the Jan 5, 2026 J-code update drew negative next-day moves. A prior conference appearance on Nov 25, 2025 had a modest positive reaction, comparable in type to today’s summit presentation news.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit to take place on February 11-12, 2026.
Guggenheim Emerging Outlook: Biotech Summit 2026
| Date / Time: | February 12, 2026, at 2:30 PM ET |
| Format: | Fireside Chat and 1x1 investor meetings |
| Location: | New York, NY |
| Webcast Link: | here |
The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. To learn more, visit www.urogen.com or follow us on X (Twitter), @UroGenPharma
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
